Company
Headquarters: Santa Clara, CA, United States
Employees: 352
CEO: Ms. Laura A. Francis
$787.1 Million
USD as of July 1, 2025
| Company | Market Cap (USD) |
|---|---|
| Abbott | $233.33 B |
| Boston Scientific Corporation | $154.34 B |
| Stryker | $151.06 B |
| Medtronic | $113.25 B |
| Edwards Lifesciences Corporation | $45.05 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
| Last Financial Reports Date | Dec. 31, 2023 |
| Revenue TTM | $138.9 M |
| EBITDA | $-41,503,000 |
| Gross Profit TTM | $109.4 M |
| Profit Margin | -31.20% |
| Operating Margin | -32.18% |
| Quarterly Revenue Growth | 21.60% |
SI-BONE, Inc. has the following listings and related stock indices.
Stock: NASDAQ: SIBN wb_incandescent
Stock: FSX: 2K3 wb_incandescent
Stock: Munich: 2K3 wb_incandescent